Scholars Central

Conference abstractPublished 2 Jul 2012

Predictive biomarkers for development of antibody-drug conjugates

Authors: Omar Kabbarah

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Antibody-drug conjugates hold tremendous promise in Oncology. Through selectively targeting tumor cells with lethal payloads while largely sparing normal cells from unwanted toxicities, this class of "smart drug" could offer meaningful clinical relief to patients suffering from cancer. For the therapeutic potential of ADCs to be fully realized, however, it is vital that the development of these compounds be coupled with a diagnostic can be used to identify patients who are likely to experience clinical benefit, as well as those who are not likely to respond to the ADC and would be better served to pursue other treatment options. Diagnostic approaches from Genentech's ADC pipeline will be presented.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Molecular Biomarkers & Diagnosis
  • SubjectGenetics & Molecular Biology
  • SubjectPathology & Lab Medicine
  • BylineArticles whose byline prints “Omar Kabbarah”